127 related articles for article (PubMed ID: 7734308)
1. Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.
Rehn S; Gronowitz JS; Källander C; Sundström C; Glimelius B
Br J Cancer; 1995 May; 71(5):1099-105. PubMed ID: 7734308
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of proliferation-associated parameters in B-cell non-Hodgkin lymphoma.
Rehn S; Glimelius B; Sundström C
Hematol Oncol; 1991; 9(6):287-98. PubMed ID: 1748395
[TBL] [Abstract][Full Text] [Related]
3. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.
Hallek M; Emmerich B; Strohmeyer S; Busch R; Reichle A; Senekowitsch R
Klin Wochenschr; 1988 Aug; 66(16):718-23. PubMed ID: 3172680
[TBL] [Abstract][Full Text] [Related]
4. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of serum-markers in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin lymphomas.
Martinsson U; Glimelius B; Hagberg H; Sundström C
Eur J Haematol; 1988 Apr; 40(4):289-98. PubMed ID: 3366218
[TBL] [Abstract][Full Text] [Related]
6. Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers.
Gronowitz JS; Steinholtz L; Källander CF; Hagberg H; Bergh J
Cancer; 1986 Jul; 58(1):111-8. PubMed ID: 3011236
[TBL] [Abstract][Full Text] [Related]
7. Lack of correlation between thymidine kinase activity and changes of DNA synthesis with tumour age: an in vivo study in Ehrlich ascites tumour.
Skog S; He Q; Tribukait B
Cell Tissue Kinet; 1990 Nov; 23(6):603-17. PubMed ID: 2276175
[TBL] [Abstract][Full Text] [Related]
8. Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma.
Madewell BR
J Vet Intern Med; 2004; 18(5):595-6. PubMed ID: 15515571
[TBL] [Abstract][Full Text] [Related]
9. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications.
Hallek M; Wanders L; Strohmeyer S; Emmerich B
Ann Hematol; 1992 Jul; 65(1):1-5. PubMed ID: 1643153
[TBL] [Abstract][Full Text] [Related]
10. An in-house assay for serum deoxythymidine kinase.
Seah LH; Ton SH; Cheong SK; Hamidah NH
Malays J Pathol; 1991 Dec; 13(2):109-13. PubMed ID: 1823092
[TBL] [Abstract][Full Text] [Related]
11. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients.
Bogni A; Cortinois A; Grasselli G; Seregni E; Crippa F; Castellani MR; Bombardieri E
J Biol Regul Homeost Agents; 1994; 8(4):121-5. PubMed ID: 7660854
[TBL] [Abstract][Full Text] [Related]
12. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia.
Källander CF; Simonsson B; Hagberg H; Gronowitz JS
Cancer; 1984 Dec; 54(11):2450-5. PubMed ID: 6498737
[TBL] [Abstract][Full Text] [Related]
13. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
[TBL] [Abstract][Full Text] [Related]
14. Primarily asymptomatic low-grade non-Hodgkin lymphomas: prediction of symptom-free survival and total survival.
Martinsson U; Glimelius B; Hagberg H; Sundström C
Eur J Haematol; 1989 Oct; 43(4):332-8. PubMed ID: 2583259
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma.
Simonsson B; Källander CF; Brenning G; Killander A; Ahre A; Gronowitz JS
Br J Haematol; 1985 Oct; 61(2):215-24. PubMed ID: 4041368
[TBL] [Abstract][Full Text] [Related]
16. Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas.
Lehtinen T
Cancer Detect Prev; 1988; 12(1-6):125-31. PubMed ID: 3052829
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of serum lactic dehydrogenase levels and fraction of S-phase cells in non-Hodgkin lymphomas.
Lindh J; Lenner P; Osterman B; Roos G
Eur J Haematol; 1993 May; 50(5):258-63. PubMed ID: 8319787
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of plasma levels of thymidine kinase and mutated p53 in 81 patients with newly diagnosed malignant lymphoma.
Lehtinen T; Aine R; Kellokumpu-Lehtinen P; Hakala T; Lehtinen M
Acta Oncol; 1993; 32(7-8):779-81. PubMed ID: 8305226
[TBL] [Abstract][Full Text] [Related]
19. 'Aggressive' low grade lymphocytic lymphomas can be identified by flow cytometric S-phase determinations.
Lindh J; Jonsson H; Lenner P; Roos G
Hematol Oncol; 1992; 10(3-4):171-9. PubMed ID: 1398513
[TBL] [Abstract][Full Text] [Related]
20. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.
Gronowitz JS; Hagberg H; Källander CF; Simonsson B
Br J Cancer; 1983 Apr; 47(4):487-95. PubMed ID: 6849793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
